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Introduction
Neurosurgical patients have a high risk of developing nosoco-
mial meningitis, with potentially lethal consequences. The wide-
spread use of antibiotics may have altered the epidemiology of
post-neurosurgical meningitis in recent years.1,2 During the past
three decades, Acinetobacter baumannii has emerged as an
infectious agent of importance in hospitals worldwide, due to
its ability to tolerate desiccation and to accumulate diverse
mechanisms of resistance.3
We report the case of a neurosurgical patient who developed
meningitis due to multidrug-resistant (MDR) A. baumannii that
was cured by intrathecal colistin, and contextualize it among all
the published cases of Acinetobacter meningitis treated with
intrathecal or intraventricular colistin found through a MEDLINE
search of the international literature from 1950 to date.
Case report
A36-year-oldmanwas admitted to the intensive care unit (ICU)
with a complex craniofacial trauma resulting from a recreational
fireworks blast. The injuries involved the anterior skull base with
exposure and severe damage to the dura mater and brain, loss of
orbital contents, cerebrospinal fluid (CSF) leak, and soft tissue and
facial skin loss. On admission, the patient was comatose with a
Glasgow coma scale score of 7/15. He was intubated under
sedation, and ventilation and oxygenation were supported by
mechanical ventilation.
An urgent craniotomy was performed for the evacuation of
hematomas, debridement of cortical contusions, and repair of the
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Introduction: Post-neurosurgical nosocomial meningitis has become an important subgroup of bacterial
meningitis in the hospital setting. The increase in meningitis caused by multidrug-resistant (MDR)
Acinetobacter baumannii has resulted in a significant reduction in available treatment options.
Case report and literature review: We report the case of a 36-year-old man with a complex craniofacial
trauma, who developed a nosocomial meningitis due to MDR A. baumannii that was cured by intrathecal
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with topical colistin found through a MEDLINE search of the literature. To date, including the present
case, eight reported cases of Acinetobactermeningitis have been treatedwith colistin administered by an
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dura mater. At this time, a lumbar drainage was inserted to
maintain a low CSF pressure and facilitate healing.
Perioperative antibiotic chemoprophylaxis with cefazolin was
started, and considering the patient’s condition, it was prolonged.
On the third day after surgery the patient presentedwith remittent
fever (peak 38.8 8C), but no source of infection could be found on
physical examination and imaging studies. Laboratory examina-
tions revealed a white blood cell (WBC) count of 14.1  109/l with
72% neutrophils and 23% lymphocytes. Cultures of blood, central
venous catheter, arterial line, tracheal aspirate, bronchial alveolar
lavage, and urine were drawn and subsequently found to be
negative. Results of urinalysis were unremarkable. Pending the
culture results, the patient was empirically treated with intrave-
nousmeropenem and teicoplanin. The patient’s CSF was clear with
a glucose concentration of 16 mg/dl, a protein level of 380 mg/dl,
and a WBC count of 300  106/l, with 95% polymorphonuclear
leukocytes and 5% lymphocytes. Gram staining of the CSF revealed
no organisms.
Three days later, a culture of CSF yielded A. baumannii. The
bacteria were identified by morphology, Gram stain, and
reactions with the Vitek 2 GNI card (bioMe´rieux-Vitek). It was
resistant to all the antibiotics examined in the laboratory by disk
diffusion susceptibility test, including carbapenems, cephalos-
porins, fluoroquinolones, aminoglycosides, and aztreonam,
and sensitive only to colistin. Susceptibility to sulbactam and
tigecycline was not tested.
Once the organism was identified, parenteral therapy was
discontinued and intrathecal colistin 10 mg/day was started.
The colistin dose was diluted in 2 ml of sterile normal saline
and given through the lumbar drainage after removal of a greater
or equal volume of CSF. After each dose, the lumbar drainage was
clamped for 1 h and released.
The patient became afebrile at 48 h after the beginning of
intrathecal colistin. CSF cultures performed daily became negative
after 5 days of intrathecal therapy and on that day the CSF WBC
count had decreased to 100  106/l. On day 10, CSF culture
continued to be sterile, the CSFWBC count had further decreased to
8  106/l, and hence the lumbar drainage was removed and the
therapy stopped. No complications or side effects were observed
during the treatment. Renal function was stable. The patient’s
clinical status progressively improved and the maxillofacial
surgery team began the orbitocranial reconstruction. After one
month, the patient was discharged from the hospital with
moderate neuropsychological consequences. The patient has been
followed up for two years, with no evidence of relapse or CSF leak.
The clinical data for our patient are summarized in the last
row of Table 1.
Literature review and discussion
For the review of published cases, a PubMed search was
performed combining the terms (polymyxins OR polymyxin OR
colistin) AND (meningitis OR ventriculitis OR intrathecal OR intra
thecal OR intraventricular OR intra ventricular OR intraspinal OR
intracerebral) AND (Acinetobacter OR Achromobacter) for the
period January 1950 to April 2009; references were also checked
for relevant articles, including review papers.
A study was considered eligible for inclusion in the systematic
review if it reported data on the clinical effectiveness and/or safety
of intraventricular or intrathecal colistin for the treatment of
patients with meningitis caused by MDR Acinetobacter.
Our search identified 45 potentially relevant articles. After a
scrupulous analysis of all studies, 18 articles describing 33
episodes of Acinetobacter meningitis occurring in 31 patients on
all five continents, published between the years 1990 and 2009,
were further evaluated together with our patient data. Data
regarding the clinical characteristics, therapy, and outcome of
these patients are shown in Table 1.4–22 Of note, not one paper
reporting cases of Acinetobacter meningitis treated intraventri-
cularly or intrathecally was excluded; in all these cases the authors
considered the Acinetobacter as MDR.
In some papers the term ‘intrathecal’ was improperly used for
cases treated intraventricularly. In this review the patients were
classified according to theway inwhich theywere actually treated,
independently of the way the authors used the terms. Further-
more, we used the term ‘topical colistin’ to refer to both means of
administration, intrathecal and intraventricular.
In one patient, the species involved was Acinetobacter
calcoloaceticus;6 in all the others A. baumannii. In two patients,
other bacteria were also isolated from the CSF cultures:
methicillin-resistant Staphylococcus aureus and Enterobacter cloa-
cae in one patient and Staphylococcus epidermidis in the other.7,13 In
two patients, probably due to predisposing factors, meningitis
episodes due to other bacteria also occurred.7,10 Most of the
patients (27/32) included in the reviewed studies were adults, and
for adult patients for which this information was available, the
mean age was 42.9  18 years. Of the three children, two were 4
years old and one 16 years old.4,5,13
In all the patients, meningitis was secondary to neurosurgical
procedures for the management of various central nervous system
(CNS) diseases, often resulting from a head injury. Colonization of a
ventriculoperitoneal (VP) shunt with Acinetobacter was consid-
ered as the source of the infection in two patients.7,8
Minimum inhibitory concentration (MIC) values for colistin
and/or other antibiotics were reported in only two cases.18,21
Strains with intermediate resistance to carbapenems were
reported in two cases.5,10 Intravenous carbapenems were initially
used in nine patients. In none of the articles were strains tested for
their ability or inability to form a biofilm. Colistin was
administered intraventricularly by external ventricular drainage
(EVD) or by an externalization of a VP shunt in 24 cases,4,5,7,9–
11,13,14,17–21 and intrathecally by an external lumbar drainage or by
lumbar puncture in seven patients (eight including the present
case).6,8,12,13,15,16
Even though colistin was the only antibiotic to which the
organism was susceptible in many cases, topical colistin was used
from the beginning of therapy in only four cases.5,6,12,15 Mono-
therapy with topical colistin was the final therapeutic regimen in
eight cases,6,9,12–14,21 and combination of systemic and topical
colistin in 13 cases.8,11,16,17,20 In one patient, intrathecal colistin
was combined with intravenous rifampin.15 In the remaining
episodes, various combinations of topical colistin with systemic
and/or topical antibiotics of other categories were administered.
There was considerable variability in the daily dose and dosing
scheme of colistin administered by the intrathecal or intraven-
tricular route in the reviewed studies. In adults and in the 16-year-
old boy, the daily dose of colistin ranged from 1.6 mg every 24 h to
20 mg every 24 h. In the 4-year-old child treated intrathecally, the
colistin dose was 1 mg on the first day increasing to 4 mg on the
fourth day, continued for 13 days.13 In six out of the eight cases
treated intrathecally and in four out of the 24 cases treated
intraventricularly, the first dosewas half of the daily dose. In all the
cases treated intrathecally and in 11 out of 24 cases treated
intraventricularly, topical colistin was administered in a single
daily dose, in the other patients it was administered in two divided
doses. The duration of treatment also varied greatly, approxi-
mately ranging from3 to 42 days. In the caseswhere therapy lasted
less than 7 days, this was due to the death of the patient or for the
occurrence of side effects.13,18
In all the cases, CSF cultures became negative during treatment
with topical colistin. The median time necessary to obtain CSF
sterilization was 4.1 days (range 1–15 days), and all the episodes
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could be considered cured, even if in two cases Acinetobacter
meningitis relapsed. In one patient with recurrent episodes of
meningitis, A. baumannii reappeared in the CSF 40 days after
microbiological cure.10 In another patient, A. baumannii reap-
peared in the CSF when the colistin dose was reduced.16 Both the
patients were successfully retreated, one with a combination of
antibiotics, including intraventricular colistin, and the other with
intrathecal and IV colistin.
Five patients died of causes not related to meningitis or its
treatment.5,11,13,18,19
Toxicity probably or possibly related to the topical adminis-
tration of colistin was noted in five patients: in three cases, a
reversible ventricular or meningeal irritation was reported,
manifested by neurological symptoms/signs and an increase in
the cell count in the CSF, despite negative cultures. In one case,
unspecified neurological disorders appeared after four days of
intraventricular treatment, making it necessary the discontinue
treatment;13 and in the other case, an episode of seizure
immediately after the administration of an 8 mg intrathecal dose
made it necessary to reduce the colistin dose.8
Characteristics of the patients grouped on the basis of the route
of colistin administration are compared in Table 2. Within the
limits of a statistical analysis performed on groups of scattered
cases, we tried to analyze the numeric differences. The daily dosage
and the total amount of colistin administered were higher in
patients treated intraventricularly (t-test, p = 0.05 and p = 0.03,
respectively). The time for culture sterilization was shorter in the
subgroup treated intrathecally (t-test, p = 0.05). Side effects
occurred more frequently in the subgroup treated intrathecally
(Chi-square, p = 0.11). No relapse was observed in the eight
patients in which topical colistin (four patients treated intrathe-
cally and four patients treated intraventricularly), was the only
microbiologically active drug.
In only seven of the retrieved papers were data on the
management of external drainage catheters and shunts clearly
reported, and in only one case was the patient’s EVD replaced with
a drain at a new site due to minimal clinical response and little
change in the CSF cultures.8
Acinetobacter spp is a Gram-negative coccobacillus that, during
the past three decades, has emerged from an organism of
questionable pathogenicity to an infectious agent of importance
in hospitals worldwide.3 The organism’s ability to tolerate
desiccation and to accumulate diverse mechanisms of resistance
favor its long-term persistence in ICUs, where skin carriage may
persist for weeks/months and the Acinetobacter-colonized hands
of the staff may be responsible for patient-to-patient spread.
Environmental contamination and contamination of medical
equipment may also play an important role in the transmission
of A. baumannii in healthcare institutions.1,3
Bacterial meningitis caused by A. baumannii constitutes around
10% of Gram-negative and 4% of nosocomial meningitis.23 The
mortality rate of patients with neurosurgery-related Gram-
negative meningitis is about 33%.24 The mortality rate in patients
with Acinetobactermeningitis treated only parenterally (without a
topical administration of colistin) is about 27%.25 Only five out of
the 32 (15.6%) patients we considered in our review died, and for
none of themwas the death considered to be related to meningitis
or its treatment.
The presence of multiresistance and the poor penetration of
many drugs through the blood–brain barrier have forced the use of
topical therapies, initiallywith aminoglycosides andmore recently
with colistin. The combination of topical and intravenous amikacin
has been associated with a survival rate of less than 60%.17,26,27
Colistin (polymyxin E) is available in vials containing one
million units corresponding to 80 mg of colistimethate (1 mg = 12
500 IU). There is much uncertainty surrounding the penetration of
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colistin into the CSF, and its use only by intravenous route is not
recommended for the treatment of Acinetobacter meningitis.25
The manufacturer does not suggest intrathecal administration;
however, administration into the CNS is associated with a
favorable outcome in a considerable proportion of patients.
Falagas et al. have summarized the evidence regarding the
intrathecal and intraventricular use of polymyxins in an excellent
systematic review of the literature.28 Treating CNS infections with
topical colistin alone will avoid the significant renal toxicity
associated with the intravenous route of administration.
Guidelines published by the Infectious Diseases Society of
America (IDSA) in 2004, suggest that the intraventricular dosage of
colistin should be 10 mg every 24 h.29 However, it should be
mentioned that, to the best of our knowledge, no antimicrobial
agent has been approved by the Food and Drug Administration
(FDA) for intrathecal or intraventricular use.
It should be remembered that CSF volumes of distribution of
neurosurgical patients vary considerably, thus varying the
therapeutic dose. EVD rates are widely variable—in those with
excessive drainage, topical antibiotics will be diluted more, and
conversely if drainage is minimal, higher levels and possibly
greater toxicity may result.13 We, as did most of the authors of the
collected papers, clamped the drainage for 1 h to deal with the
problem of excessive drainage. Furthermore, attention should be
paid to the volume in the drainage pipe; after the antibiotic
administration, the drainage tube should be filled with saline
solution to avoid that part of the infused drug not reaching the
subarachnoid space.
From the analysis of the retrieved cases, data are insufficient to
establish whether only colistin through a topical route or a
combination of topical colistin and intravenous colistin is more
advantageous to treat Acinetobacter meningitis. We believe that
the only rationale for adding intravenous colistin would be an
attempt to sterilize the possible site of infection or colonization.
Interestingly, Motaouakkil et al. used the combination of
intravenous rifampin and topical colistin.15 Rifampin has an
excellent CSF penetration.30 Colistin and rifampin appeared to be
an effective and safe combination therapy for severe human
infections due to MDR A. baumannii.31 However, insufficient data
exist to recommend this association for the treatment of MDR
Acinetobacter meningitis.
Topical administration of colistin is currently withheld as a last
treatment option for MDR Acinetobacter meningitis, probably due
to the doctor’s fear of side effects. In fact, topical colistin was well
tolerated, reversible chemical meningitis being the most common
form of toxicity reported and irreversible toxicity not reported in
any study.
We believe that topical colistin should be initiated without
delay. From the analysis of the retrieved papers, data are too scarce
to yield a meaningful analysis of shunt management. However,
considering the possibility of biofilm-forming strains,32 shunt
removal may be an important adjunct to treatment of post-
neurosurgical Acinetobacter meningitis in patients with ventri-
cular shunts.25
We think that when feasible, in cases of meningitis or
ventriculitis, especially if external devices are implanted, the
intraventricular route should be preferred to the intrathecal route,
for at least the following two reasons: (1) For a drug administered
intrathecally, it is more difficult to obtain a high concentration in
the ventricular system; in fact, the CSF circulates from the
ventricular system to the cerebellomedullary cistern and then
down the spinal cord. (2) From the analysis of the reviewed cases,
as shown in Table 2, chemical ventriculitis andmeningitis occurred
in one case out of 24 patients (4.2%) treated intraventricularly and
in two out of eight cases (25%) treated intrathecally.
Data are insufficient to determine whether the strategy of a
reduced first dose adopted by many authors, probably to test for
tolerability, ismeaningful or not. Neither can conclusions be drawn
regarding the duration of topical colistin treatment. Even if the CSF
sterilizationwas obtained after fewer than 5 days of therapy in 75%
of the reported cases, we think that when possible, the
recommendations of IDSA should be followed, and that anti-
microbial therapy be continued until CSF culture results remain
negative for 10–14 consecutive days before a new CSF shunt (if
necessary) is placed.29
In conclusion, our case along with the available evidence
suggests that topical colistin can be an effective and safe treatment
for the management of MDR Acinetobacter meningitis.
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